From Wikipedia, the free encyclopedia
|Mol. mass||145.2 kDa|
|(what is this?)|
Rilotumumab is a human monoclonal antibody designed for the treatment of solid tumors.
Rilotumumab was developed by Amgen, Inc.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab". American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|